NO333265B3 - Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne. - Google Patents

Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne.

Info

Publication number
NO333265B3
NO333265B3 NO20055649A NO20055649A NO333265B3 NO 333265 B3 NO333265 B3 NO 333265B3 NO 20055649 A NO20055649 A NO 20055649A NO 20055649 A NO20055649 A NO 20055649A NO 333265 B3 NO333265 B3 NO 333265B3
Authority
NO
Norway
Prior art keywords
compound
preparation
drug containing
dihydroquinazolines
substituted
Prior art date
Application number
NO20055649A
Other languages
English (en)
Other versions
NO20055649L (no
NO20055649D0 (no
NO333265B1 (no
Inventor
Rudolf Schohe-Loop
Rolf Grosser
Kerstin Henninger
Jörg Keldenich
Thomas Lampe
Holger Zimmermann
Tobias Wunberg
Judith Baumeister
Ulrich Betz
Mario Jeske
Susanne Nikolic
Jürgen Reefschlager
Frank Süssmeier
Guy Hewlett
Dieter Lang
Peter Nell
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of NO20055649D0 publication Critical patent/NO20055649D0/no
Publication of NO20055649L publication Critical patent/NO20055649L/no
Publication of NO333265B1 publication Critical patent/NO333265B1/no
Publication of NO333265B3 publication Critical patent/NO333265B3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20055649A 2003-05-02 2005-11-30 Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne. NO333265B3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline
PCT/EP2004/004103 WO2004096778A1 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften

Publications (4)

Publication Number Publication Date
NO20055649D0 NO20055649D0 (no) 2005-11-30
NO20055649L NO20055649L (no) 2006-01-31
NO333265B1 NO333265B1 (no) 2013-04-22
NO333265B3 true NO333265B3 (no) 2019-06-03

Family

ID=33305099

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20055649A NO333265B3 (no) 2003-05-02 2005-11-30 Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne.
NO2018022C NO2018022I1 (no) 2003-05-02 2018-07-04 Letermovir, eller dets salt, solvat eller solvat av dets salt

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2018022C NO2018022I1 (no) 2003-05-02 2018-07-04 Letermovir, eller dets salt, solvat eller solvat av dets salt

Country Status (39)

Country Link
US (4) US7196086B2 (no)
EP (1) EP1622880B3 (no)
JP (1) JP4733631B2 (no)
KR (1) KR100927063B1 (no)
CN (1) CN100393706C (no)
AR (1) AR044078A1 (no)
AT (1) ATE355280T1 (no)
AU (1) AU2004233978B2 (no)
BR (1) BRPI0410029B8 (no)
CA (1) CA2524069C (no)
CL (1) CL2004000930A1 (no)
CO (1) CO5700764A2 (no)
CY (2) CY1106476T1 (no)
DE (2) DE10319612A1 (no)
DK (1) DK1622880T6 (no)
EC (1) ECSP056138A (no)
EG (1) EG25273A (no)
ES (1) ES2284007T7 (no)
FR (1) FR18C1029I2 (no)
HK (1) HK1092463A1 (no)
HN (1) HN2004000146A (no)
HU (2) HUS1800018I1 (no)
IL (1) IL171513A (no)
MA (1) MA27794A1 (no)
MX (1) MXPA05011707A (no)
MY (1) MY144616A (no)
NL (1) NL300933I2 (no)
NO (2) NO333265B3 (no)
NZ (1) NZ543317A (no)
PE (1) PE20050145A1 (no)
PL (1) PL1622880T6 (no)
PT (1) PT1622880E (no)
RU (1) RU2360912C2 (no)
SI (1) SI1622880T1 (no)
TW (1) TWI335912B (no)
UA (1) UA82519C2 (no)
UY (1) UY28294A1 (no)
WO (1) WO2004096778A1 (no)
ZA (1) ZA200508710B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
CA2916143C (en) * 2013-06-19 2019-01-29 Aicuris Anti-Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
WO2015088931A1 (en) * 2013-12-12 2015-06-18 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
WO2017091453A1 (en) * 2015-11-24 2017-06-01 Merck Sharp & Dohme Corp. Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts
CN109476677B (zh) 2016-08-08 2024-06-07 辉诺生物医药科技（杭州）有限公司 抗hcmv病毒化合物
US11174270B2 (en) 2018-02-08 2021-11-16 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
CN112996789A (zh) 2018-09-12 2021-06-18 诺华股份有限公司 抗病毒吡啶并吡嗪二酮化合物
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
AR121440A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método de preparación de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, dicho compuesto y el uso del mismo para el tratamiento de infecciones virales
AR121438A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
AR121437A1 (es) * 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético
UY39096A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
US20230312485A1 (en) 2020-08-17 2023-10-05 Lupin Limited A precipitation process for amorphous letermovir
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
WO2023185597A1 (zh) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A2 (en) * 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
US6495578B1 (en) 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
AU2001283955B2 (en) 2000-07-31 2006-05-18 F. Hoffmann-La Roche Ag Piperazine derivatives
ES2252455T3 (es) 2001-04-19 2006-05-16 Bayer Healthcare Ag Arilsulfonamidas como agentes antivirales.
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
JP5139083B2 (ja) * 2005-01-25 2013-02-06 プロレキシーズ ファーマシューティカルズ インコーポレイテッド 抗腫瘍剤としてのキノキサリン誘導体
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
ATE449097T1 (de) 2005-07-21 2009-12-15 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
CA2916143C (en) * 2013-06-19 2019-01-29 Aicuris Anti-Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A2 (en) * 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARINEZ, A. ET AL.Benzothiadiazine dioxide human cytomegalovirus inhibitors: synthesis and antiviral evaluation of main heterocycle modified derivatives.Antiviral Chemistry & Chemotherapy. 2003, 14(2) s. 107-114., Dated: 01.01.0001 *

Also Published As

Publication number Publication date
DE10319612A1 (de) 2004-11-18
EP1622880B3 (de) 2018-05-23
WO2004096778A1 (de) 2004-11-11
ZA200508710B (en) 2006-12-27
KR100927063B1 (ko) 2009-11-13
ES2284007T3 (es) 2007-11-01
HUS1800028I1 (hu) 2018-07-30
US20070191387A1 (en) 2007-08-16
DK1622880T3 (da) 2007-06-25
EP1622880B1 (de) 2007-02-28
CY2018019I1 (el) 2018-12-12
CN1784390A (zh) 2006-06-07
CY1106476T1 (el) 2012-01-25
NO2018022I1 (no) 2018-07-04
NZ543317A (en) 2008-05-30
CN100393706C (zh) 2008-06-11
BRPI0410029A (pt) 2006-04-25
AU2004233978B2 (en) 2010-02-11
PL1622880T6 (pl) 2018-08-31
PT1622880E (pt) 2007-06-04
BRPI0410029B1 (pt) 2019-12-31
USRE46791E1 (en) 2018-04-17
NO20055649L (no) 2006-01-31
HK1092463A1 (en) 2007-02-09
RU2005137276A (ru) 2006-07-27
HN2004000146A (es) 2008-06-24
MA27794A1 (fr) 2006-03-01
HUS1800018I1 (hu) 2018-05-28
CL2004000930A1 (es) 2005-03-18
FR18C1029I2 (fr) 2020-07-17
KR20060009883A (ko) 2006-02-01
ES2284007T7 (es) 2018-06-20
CA2524069A1 (en) 2004-11-11
BRPI0410029B8 (pt) 2021-06-15
FR18C1029I1 (no) 2018-08-17
MY144616A (en) 2011-10-14
USRE49698E1 (en) 2023-10-17
JP4733631B2 (ja) 2011-07-27
NO20055649D0 (no) 2005-11-30
US7196086B2 (en) 2007-03-27
CA2524069C (en) 2011-11-08
ATE355280T1 (de) 2006-03-15
EG25273A (en) 2011-12-04
DK1622880T6 (da) 2018-06-18
UY28294A1 (es) 2004-11-30
CO5700764A2 (es) 2006-11-30
AR044078A1 (es) 2005-08-24
AU2004233978A1 (en) 2004-11-11
MXPA05011707A (es) 2006-02-13
ECSP056138A (es) 2006-04-19
US8513255B2 (en) 2013-08-20
RU2360912C2 (ru) 2009-07-10
PE20050145A1 (es) 2005-05-22
SI1622880T1 (sl) 2007-08-31
TWI335912B (en) 2011-01-11
EP1622880A1 (de) 2006-02-08
TW200510343A (en) 2005-03-16
UA82519C2 (uk) 2008-04-25
NO333265B1 (no) 2013-04-22
NL300933I2 (nl) 2018-04-26
PL1622880T3 (pl) 2007-08-31
DE502004003052D1 (de) 2007-04-12
IL171513A (en) 2011-11-30
US20050065160A1 (en) 2005-03-24
JP2006525249A (ja) 2006-11-09
CY2018019I2 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
NO333265B3 (no) Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne.
NO2012017I1 (no) Benzimidazolderivat, fremgangsmåte for fremstilling derav, medikament inneholdende denne forbindelsen samt anvendelse av forbindelsen.
NO20053150D0 (no) System for administrasjon av medisin.
NO20093060L (no) Spirosykliske sykloheksanderivater
CY2014008I1 (el) Παραγωγα κιναζολινης, φαρμακα που περιεχουν τις ενωσεις αυτες χρηση αυτων και μεθοδους για την παραγωγη τους
NO20032733D0 (no) Difenyl azetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
NO20032735D0 (no) Difenyl azetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
WO2003080582A3 (de) Fredericamycin-derivate
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
HK1090042A1 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the of the same as medicaments, and medicament containing such compounds
EE200300077A (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
NO20054762L (no) Polymorphs of aripiprazole
NO20090294L (no) Spirocykliske azaindolderivater
WO2005021496A3 (en) Synthesis of derivatives of ginkgolide c
DK1838315T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til fremstilling heraf, deres anvendelse som medikament samt medikamenter indeholdende dem
NO20025686D0 (no) Storsekk, samt fremgangsmåte til fremstilling av denne
WO2004105773A3 (en) Use of s1p
DK1494650T3 (da) Farmaceutisk formulering, der indeholder melatonin
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
TW200503759A (en) Tablets comprising flavourings and/or aromatizing substances

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AICURIS ANTI-INFECTIVE CURES GMBH, DE

CREP Change of representative

Representative=s name: TANDBERG INNOVATION AS, POSTBOKS 1570 VIKA, 0118 O

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: LETERMOVIR, ELLER DETS SALT, SOLVAT ELLER SOLVAT AV DETS SALT; REG. NO/DATE: EU/1/17/1245 20180205

Spc suppl protection certif: 2018022

Filing date: 20180704

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: LETERMOVIR, ELLER DETS SALT SOLVAT ELLER SOLVAT AV DETS SALT; REG. NO/DATE: EU/1/17/1245 20180205

Spc suppl protection certif: 2018022

Filing date: 20180704

Extension date: 20290417

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AIC246 AG & CO. KG, DE

SPCS Change of name or address of the owner of a supplementary protection certificate

Owner name: AIC246 AG & CO. KG, DE

Spc suppl protection certif: 2018022